Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study

Plain-language summary

Published 2023 in Geriatr Gerontol Int, this work by Akasaka H and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

• Human study published in Geriatr Gerontol Int (2023) examining Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physic...
• Provides clinical-grade evidence on NAD+/NMN-related outcomes in human participants
• First author: Akasaka H; cited frequently in NMN supplementation discussions

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to benefits decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.